Hydrocephalus Shunt Valve Sales

Hydrocephalus Shunt Valve Sales Market Outlook

The global Hydrocephalus Shunt Valve market is projected to reach approximately USD 1.5 billion by 2035, with a compound annual growth rate (CAGR) of around 5.2% during the forecast period of 2025 to 2035. The market's growth is primarily driven by the increasing prevalence of hydrocephalus, advancements in shunt technologies, and the rising awareness regarding neurogenic disorders. Furthermore, the growing geriatric population, who are more susceptible to conditions such as Normal Pressure Hydrocephalus (NPH), is expected to contribute significantly to the market expansion. Additionally, the surge in demand for minimally invasive surgical procedures is propelling the adoption of hydrocephalus shunt valves across various medical facilities worldwide. The ongoing research initiatives aimed at enhancing the efficacy and safety of these devices are also poised to boost market growth significantly.

Growth Factor of the Market

One of the primary growth factors for the Hydrocephalus Shunt Valve market is the escalating incidence of hydrocephalus worldwide, which has necessitated improved medical interventions and devices. With a rising number of patients diagnosed with hydrocephalus, the healthcare sector is increasingly recognizing the need for effective shunt valve systems to manage cerebrospinal fluid (CSF) flow. Moreover, technological advancements, such as the development of programmable and adjustable valves, have allowed for more tailored treatment options, enhancing patient outcomes and safety. Additionally, the growing preference for outpatient procedures has catalyzed the demand for innovative, user-friendly shunt systems that can be deployed in various clinical settings, further driving market growth. Investment in research and development aimed at creating more efficient materials and designs for shunt valves is also expected to propel the industry forward, satisfying the evolving needs of healthcare providers and patients alike.

Key Highlights of the Market

• Increasing prevalence of hydrocephalus, especially in the aging population.
• Technological advancements leading to the development of innovative shunt valves.
• Rising awareness among healthcare professionals regarding hydrocephalus management.
• Growing preference for minimally invasive surgical techniques.
• Expansion of distribution channels to enhance accessibility of shunt valves.

By Product Type

Adjustable Valves:

Adjustable valves are designed to allow clinicians to modify the pressure settings post-implantation, offering significant advantages in the management of hydrocephalus. This flexibility helps in addressing varying patient needs and ensures optimal CSF flow regulation. The growing adoption of adjustable valves can be attributed to their efficacy in preventing complications associated with over-drainage or under-drainage of CSF. Their ability to adapt to the changing physiological states of patients has led to increased demand, contributing to their substantial market share. Moreover, advancements in the design of adjustable valves, including more reliable mechanisms and reduced risk of malfunction, further enhance their appeal to healthcare providers and patients alike.

Fixed Pressure Valves:

Fixed pressure valves remain a prominent choice in the Hydrocephalus Shunt Valve market due to their straightforward design and reliable performance. These valves are preset to a specific pressure, allowing for consistent CSF drainage without the need for adjustments. This simplicity is particularly advantageous in cases where precise pressure regulation is not as critical. The stability and reliability of fixed pressure valves have made them a staple in many surgical procedures, particularly in developing regions where access to advanced healthcare technology may be limited. As the understanding of hydrocephalus continues to evolve, the market for fixed pressure valves is expected to maintain momentum due to their established efficacy and ease of use.

Programmable Valves:

Programmable valves represent a significant innovation in the hydrocephalus management landscape, offering customizable pressure settings that can be modified non-invasively. These valves enable healthcare professionals to tailor treatment to individual patient needs, thereby enhancing therapeutic outcomes. The convenience of being able to adjust the valve settings through an external programmable device minimizes the need for additional surgical interventions. The growing trend towards patient-centered care and personalized medicine is driving demand for programmable valves, as they provide a more adaptable solution for managing hydrocephalus. As awareness and understanding of these advanced technologies increase, the market for programmable valves is anticipated to grow robustly.

Combination Valves:

Combination valves, which integrate features of both fixed and adjustable mechanisms, have emerged as a popular choice among surgeons seeking versatile solutions for hydrocephalus management. These valves offer the stability of fixed pressure valves while providing the option for adjustments when necessary. The dual-functionality makes them particularly appealing in complex cases where patient conditions may change over time. The increasing complexity of hydrocephalus cases and the demand for versatile treatment options are propelling the adoption of combination valves across healthcare facilities. Their ability to seamlessly adapt to varying clinical requirements further cements their place in the hydrocephalus shunt valve market.

Gravity Valves:

Gravity valves operate based on hydrostatic pressure, utilizing gravitational forces to regulate CSF flow. This design simplifies the mechanism and minimizes the risk of complications associated with mechanical failures. Gravity valves are particularly beneficial in treating patients with specific types of hydrocephalus, such as Normal Pressure Hydrocephalus, where the management of CSF drainage is critical. The increasing focus on minimizing surgical invasiveness and optimizing patient recovery times is driving interest in gravity valves, making them a growing segment in the market. As healthcare providers seek reliable and effective solutions for hydrocephalus management, gravity valves are expected to become a more prominent choice within the sphere of shunt valves.

By Application

Normal Pressure Hydrocephalus (NPH):

Normal Pressure Hydrocephalus (NPH) is a condition characterized by an accumulation of cerebrospinal fluid (CSF) in the brain's ventricles, leading to symptoms such as cognitive decline, gait disturbances, and urinary incontinence. The specific requirements for shunt valve types in patients with NPH have spurred innovations tailored for this condition. Given the growing recognition of NPH in the medical community, the demand for effective treatment options, including specialized shunt valves, is on the rise. The increasing incidence of NPH and the subsequent need for effective management solutions are driving the growth of this application segment, as providers seek to implement shunt systems that address the unique challenges presented by this condition.

Communicating Hydrocephalus:

Communicating hydrocephalus occurs when there is a disruption in the absorption of CSF, which can lead to increased intracranial pressure despite the presence of open ventricles. The treatment typically involves the placement of shunt valves to facilitate proper drainage of CSF. The complexity of this condition necessitates the use of advanced shunt technologies that can effectively manage CSF flow and prevent complications. As awareness increases regarding the risks associated with untreated communicating hydrocephalus, the demand for specialized valves designed for this application is expected to grow. The need for innovative solutions that can mitigate the challenges associated with this condition is propelling the development and sales of shunt valves tailored to managing communicating hydrocephalus.

Non-Communicating Hydrocephalus:

Non-communicating hydrocephalus is characterized by a blockage that prevents the circulation of CSF between the ventricles, often requiring surgical intervention to restore normal flow. The treatment typically involves the implantation of shunt valves that allow for the drainage of excess CSF from the ventricles to another part of the body. The increasing prevalence of non-communicating hydrocephalus, alongside advancements in surgical techniques, is driving the demand for effective shunt valves designed specifically for this condition. As healthcare systems around the world continue to improve their capabilities in neurovascular interventions, the market for shunt valves catering to non-communicating hydrocephalus is expected to witness significant growth.

By Distribution Channel

Hospitals:

Hospitals remain the primary distribution channel for hydrocephalus shunt valves, owing to their critical role in the surgical management of hydrocephalus patients. The comprehensive facilities and medical expertise provided by hospitals make them essential for the implantation and monitoring of shunt valves. Furthermore, hospitals often have established relationships with suppliers, ensuring timely access to the latest technologies and innovations in shunt systems. As patient volumes increase and surgical interventions become more common, hospitals are anticipated to maintain a stronghold on the hydrocephalus shunt valve market, leading to ongoing investments in advanced valve technologies.

Specialty Clinics:

Specialty clinics, particularly those focusing on neurology or neurosurgery, have emerged as significant players in the hydrocephalus shunt valve distribution landscape. These clinics offer specialized care tailored to patients with hydrocephalus, often providing advanced diagnostic and treatment options. The personalized approach and focused expertise of specialty clinics attract patients seeking comprehensive management of their condition, driving demand for various shunt valves. The rise of outpatient care models and the increasing preference for specialized treatment options contribute to the growth of this distribution channel, as more patients seek care in dedicated facilities that offer cutting-edge technologies and targeted therapies.

Ambulatory Surgical Centers:

Ambulatory Surgical Centers (ASCs) have gained popularity as alternative healthcare settings for the treatment of hydrocephalus, particularly for procedures involving shunt valve implantation. These centers offer advantages such as reduced costs, shorter wait times, and the convenience of outpatient procedures. As the healthcare landscape shifts toward value-based care, ASCs are being recognized for their efficiency and effectiveness in managing simple to moderate hydrocephalus cases. The growth of ASCs is driving a greater demand for hydrocephalus shunt valves, as more patients choose to undergo procedures in these settings. The trend towards outpatient surgeries is expected to persist, further solidifying the role of ASCs in the hydrocephalus treatment continuum.

Online Sales:

The rise of e-commerce is transforming various aspects of healthcare, including the distribution of medical devices such as hydrocephalus shunt valves. Online sales platforms provide healthcare providers and patients with convenient access to a wide range of products, often at competitive prices. The increasing adoption of telemedicine and remote consultations has further emphasized the need for accessible distribution channels that can deliver shunt valves directly to practitioners or patients. As online sales options expand, manufacturers are likely to invest in direct-to-consumer strategies, which is expected to drive growth in this segment. The trend towards digital healthcare solutions indicates that online sales will continue to play a crucial role in the hydrocephalus shunt valve market.

By Material Type

Silicone Valves:

Silicone valves are widely utilized in the hydrocephalus shunt valve market due to their biocompatibility, flexibility, and resistance to degradation over time. Silicone's unique properties allow for effective CSF drainage while minimizing the risk of adverse reactions in patients. The use of silicone materials in shunt valve design also enhances the durability and longevity of these devices, which is critical in ensuring patient safety and reducing the need for surgical revisions. As the demand for reliable and safe medical devices increases, silicone valves are expected to maintain a prominent position within the hydrocephalus shunt valve market.

Polycarbonate Valves:

Polycarbonate valves are gaining traction in the hydrocephalus shunt valve market due to their lightweight nature and excellent mechanical properties. These valves are less prone to breakage compared to traditional materials, making them an appealing choice for shunt systems. The robustness of polycarbonate makes it an ideal material for various valve designs, ensuring reliable performance in challenging environments. As healthcare providers seek materials that enhance patient safety and device longevity, the adoption of polycarbonate valves is expected to rise, contributing to the overall growth of the hydrocephalus shunt valve market.

Stainless Steel Valves:

Stainless steel valves offer significant advantages in terms of strength and corrosion resistance, making them suitable for various hydrocephalus applications. The robustness of stainless steel ensures that these valves can withstand the mechanical stresses associated with CSF drainage and can be effectively sterilized for clinical use. The durability and reliability of stainless steel valves position them as a preferred option for certain patient populations. As the demand for high-performance shunt systems continues to grow, stainless steel valves are anticipated to play a vital role in the hydrocephalus shunt valve market.

Titanium Valves:

Titanium valves are increasingly being utilized in the hydrocephalus shunt valve market due to their unique combination of strength, lightweight nature, and excellent biocompatibility. The use of titanium minimizes the risk of adverse reactions in patients, making it ideal for long-term implantation. Additionally, titanium's resistance to corrosion and wear enhances the longevity of the devices, ensuring that they perform effectively throughout their intended lifespan. As advancements in materials science continue to evolve, the adoption of titanium valves is expected to expand, catering to the needs of patients requiring durable and biocompatible solutions for hydrocephalus management.

By Region

The North American region holds a significant share of the Hydrocephalus Shunt Valve market, driven primarily by high healthcare expenditure, advanced medical infrastructure, and increasing prevalence of hydrocephalus among the aging population. The region is expected to witness a CAGR of 5.8% during the forecast period, supported by continuous advancements in shunt technology and a strong focus on research and development. The presence of key manufacturers and robust distribution channels in the United States and Canada further contribute to the market's growth in this region. The combination of technological innovation and an increasing patient base emphasizes North America's pivotal role in shaping the hydrocephalus shunt valve landscape.

In Europe, the Hydrocephalus Shunt Valve market is also witnessing significant growth, attributed to the rising incidence of neurological disorders and an increasing number of surgical interventions. The European market's expansion is aided by the progressive healthcare policies and initiatives aimed at improving patient access to innovative treatment options. Countries such as Germany, the United Kingdom, and France are leading contributors to market revenue, owing to their well-established healthcare systems and strong emphasis on patient care. The overall European market is projected to grow steadily, driven by advancements in shunt valve technology and increasing collaboration between healthcare providers and manufacturers.

Opportunities

The Hydrocephalus Shunt Valve market presents numerous opportunities for growth and innovation. One significant opportunity lies in the ongoing research and development efforts aimed at creating next-generation shunt systems that are more effective, reliable, and easier to use. Manufacturers are increasingly investing in developing smart shunt valves equipped with sensors and monitoring systems that can provide real-time feedback on CSF flow, which could revolutionize the management of hydrocephalus. Such innovations could enhance patient outcomes and significantly reduce the risks associated with traditional shunt systems. Additionally, the growing trend towards personalized medicine opens up avenues for customized shunt solutions tailored to individual patient needs, further driving market growth.

Expansion into emerging markets presents another avenue for growth for the Hydrocephalus Shunt Valve market. As healthcare infrastructure improves in regions such as Asia Pacific and Latin America, there is an increasing demand for advanced medical devices, including hydrocephalus shunt valves. Engaging in strategic partnerships with local distributors and healthcare providers can facilitate market entry and enhance product visibility in these regions. Moreover, awareness initiatives aimed at educating healthcare professionals and patients about hydrocephalus can create a supportive environment for market expansion. By leveraging these opportunities, stakeholders in the hydrocephalus shunt valve market can capitalize on the rising demand for effective and innovative treatment options.

Threats

Despite the promising growth potential of the Hydrocephalus Shunt Valve market, several threats could impede its progress. One of the most significant challenges is the intense competition among manufacturers, which can lead to pricing pressures and reduced profit margins. As numerous companies strive to innovate and capture market share, the landscape becomes increasingly saturated, complicating efforts for new entrants. Furthermore, the stringent regulatory requirements governing the approval and marketing of medical devices can pose additional challenges, leading to delays in product launches and increased compliance costs. Additionally, the potential for product recalls due to safety concerns can tarnish a manufacturer's reputation and diminish consumer trust, further threatening market stability.

Restraints in the Hydrocephalus Shunt Valve market can also arise from the complexity and variability of individual patient conditions. Not all patients respond similarly to shunt valve interventions, leading to unpredictable outcomes that can complicate treatment protocols. Additionally, the reliance on surgical procedures for shunt valve placement may deter some patients from seeking treatment due to the associated risks and recovery times. Furthermore, variations in healthcare access and quality across different regions can impact the ability of patients to receive timely and effective interventions. Addressing these restraining factors will be crucial for stakeholders aiming to navigate the complexities of the hydrocephalus shunt valve market.

Competitor Outlook

• Medtronic plc
• Abbott Laboratories
• B. Braun Melsungen AG
• Codman & Shurtleff, Inc. (a subsidiary of Johnson & Johnson)
• Integra LifeSciences Corporation
• Schneider Electric
• Cook Medical
• Spiegelberg GmbH & Co. KG
• Friedrichs GmbH
• Opticore Medical
• Neurosurgical Innovations
• SurgiQuest
• REGENHU SA
• Ventris Medical
• Stryker Corporation

The competitive landscape of the Hydrocephalus Shunt Valve market is characterized by the presence of numerous established players and emerging companies, each striving to innovate and enhance their product offerings. Key players such as Medtronic, Abbott Laboratories, and B. Braun Melsungen are at the forefront of the market, leveraging their advanced research and development capabilities to introduce innovative shunt valve technologies. These companies often engage in strategic partnerships and collaborations with healthcare providers and research institutions to foster innovation and improve patient outcomes. Furthermore, the competitive environment is marked by continuous efforts to improve the design and functionality of shunt valves, with many companies focusing on developing programmable and adjustable valves to cater to the evolving needs of healthcare professionals.

Medtronic plc, as a leader in the market, has established a strong portfolio of hydrocephalus management solutions, including advanced shunt valve systems designed for optimal performance. The company continues to invest heavily in research and development to enhance the efficacy and safety of its product offerings. Similarly, Abbott Laboratories is recognized for its commitment to innovation, consistently introducing new technologies and designs that improve patient care in hydrocephalus management. B. Braun Melsungen AG, with its robust range of shunt valves, focuses on quality and reliability, ensuring that healthcare providers have access to effective solutions for managing hydrocephalus.

Emerging companies like Neurosurgical Innovations and Ventris Medical are also making significant strides in the hydrocephalus shunt valve market. These companies are often built on the foundation of innovative technologies and novel approaches to neurosurgical solutions. By focusing on user-friendly designs and cutting-edge materials, these newcomers are challenging established players and contributing to a dynamic competitive environment. Overall, the Hydrocephalus Shunt Valve market reflects a landscape of innovation and growth, as manufacturers continue to strive for improved solutions to address the challenges associated with hydrocephalus.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 REGENHU SA
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 SurgiQuest
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Cook Medical
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Medtronic plc
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Friedrichs GmbH
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Ventris Medical
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Opticore Medical
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Schneider Electric
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Abbott Laboratories
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Stryker Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 B. Braun Melsungen AG
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Neurosurgical Innovations
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Spiegelberg GmbH & Co. KG
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Integra LifeSciences Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Codman & Shurtleff, Inc. (a subsidiary of Johnson & Johnson)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Hydrocephalus Shunt Valve Sales Market, By Application
    • 6.1.1 Normal Pressure Hydrocephalus (NPH)
    • 6.1.2 Communicating Hydrocephalus
    • 6.1.3 Non-Communicating Hydrocephalus
  • 6.2 Hydrocephalus Shunt Valve Sales Market, By Product Type
    • 6.2.1 Adjustable Valves
    • 6.2.2 Fixed Pressure Valves
    • 6.2.3 Programmable Valves
    • 6.2.4 Combination Valves
    • 6.2.5 Gravity Valves
  • 6.3 Hydrocephalus Shunt Valve Sales Market, By Material Type
    • 6.3.1 Silicone Valves
    • 6.3.2 Polycarbonate Valves
    • 6.3.3 Stainless Steel Valves
    • 6.3.4 Titanium Valves
    • 6.3.5 Others
  • 6.4 Hydrocephalus Shunt Valve Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Specialty Clinics
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Online Sales

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Hydrocephalus Shunt Valve Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Hydrocephalus Shunt Valve Sales market is categorized based on

By Product Type

• Adjustable Valves
• Fixed Pressure Valves
• Programmable Valves
• Combination Valves
• Gravity Valves

By Application

• Normal Pressure Hydrocephalus (NPH)
• Communicating Hydrocephalus
• Non-Communicating Hydrocephalus

By Distribution Channel

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Online Sales

By Material Type

• Silicone Valves
• Polycarbonate Valves
• Stainless Steel Valves
• Titanium Valves
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Medtronic plc
• Abbott Laboratories
• B. Braun Melsungen AG
• Codman & Shurtleff, Inc. (a subsidiary of Johnson & Johnson)
• Integra LifeSciences Corporation
• Schneider Electric
• Cook Medical
• Spiegelberg GmbH & Co. KG
• Friedrichs GmbH
• Opticore Medical
• Neurosurgical Innovations
• SurgiQuest
• REGENHU SA
• Ventris Medical
• Stryker Corporation